scholarly journals Pharmacological and clinical profile of dexrazoxane (SAVENE® Intravenous Infusion 500 mg), a therapeutic agent for anthracycline extravasation

2015 ◽  
Vol 145 (1) ◽  
pp. 27-34
Author(s):  
Kazuyasu Maruyama ◽  
Naomi Koshihara
Keyword(s):  
Intravenous Infusion ◽  
Therapeutic Agent ◽  
Clinical Profile ◽  
Anthracycline Extravasation

scholarly journals Pharmacological and clinical profile of nitisinone (Orfadin® Capsules): a therapeutic agent for hereditary tyrosinemia type 1

2015 ◽  
Vol 146 (6) ◽  
pp. 342-348 ◽  
Author(s):  
Hideaki Minoura ◽  
Megumi Iwai ◽  
Yuta Taniuchi ◽  
Masataka Katashima ◽  
Hideyuki Takahashi
Keyword(s):  
Therapeutic Agent ◽  
Clinical Profile ◽  
Tyrosinemia Type 1 ◽  
Hereditary Tyrosinemia

Pharmacological and clinical profile of mirabegron (Betanis®): a new therapeutic agent for overactive bladder

2012 ◽  
Vol 139 (5) ◽  
pp. 219-225 ◽  
Author(s):  
Masanori Suzuki ◽  
Masashi Ukai ◽  
Masao Sasamata ◽  
Nobuo Seki
Keyword(s):  
Overactive Bladder ◽  
Therapeutic Agent ◽  
Clinical Profile

scholarly journals Pharmacological and clinical profile of ramosetron hydrochloride (Irribow®), a novel therapeutic agent for irritable bowel syndrome with diarrhea

2009 ◽  
Vol 133 (5) ◽  
pp. 281-291
Author(s):  
Takuya Hirata ◽  
Toshiyuki Funatsu ◽  
Yoshihiro Keto ◽  
Shinobu Akuzawa ◽  
Hiraku Akiho ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Agent ◽  
Clinical Profile ◽  
Irritable Bowel ◽  
Novel Therapeutic

scholarly journals Pharmacological and clinical profile of imidafenacin developed as a new therapeutic agent for overactive bladder

2008 ◽  
Vol 131 (5) ◽  
pp. 379-387 ◽  
Author(s):  
Takashi Uno ◽  
Fumiyoshi Kobayashi ◽  
Akihito Ogata ◽  
Toshihiko Konomi
Keyword(s):  
Overactive Bladder ◽  
Therapeutic Agent ◽  
Clinical Profile

scholarly journals Pharmacological and clinical profile of bixalomer (Kiklin^|^#174; capsules): a new therapeutic agent for hyperphosphatemia

2013 ◽  
Vol 141 (6) ◽  
pp. 333-337 ◽  
Author(s):  
Keiichi Taniguchi ◽  
Hirotoshi Kakuta ◽  
Yuichi Tomura ◽  
Seiji Kaku ◽  
Wataru Uchida
Keyword(s):  
Therapeutic Agent ◽  
Clinical Profile

ACE2 as therapeutic agent

2020 ◽  
Vol 134 (19) ◽  
pp. 2581-2595
Author(s):  
Qiuhong Li ◽  
Maria B. Grant ◽  
Elaine M. Richards ◽  
Mohan K. Raizada
Keyword(s):  
Therapeutic Agent ◽  
Renin Angiotensin System ◽  
Peptide Hormone ◽  
Experimental Models ◽  
Electrolyte Balance ◽  
Ang Ii ◽  
Angiotensin Converting Enzyme 2 ◽  
Beneficial Effects ◽  
Overwhelming Evidence ◽  
Future Challenges

Abstract The angiotensin-converting enzyme 2 (ACE2) has emerged as a critical regulator of the renin–angiotensin system (RAS), which plays important roles in cardiovascular homeostasis by regulating vascular tone, fluid and electrolyte balance. ACE2 functions as a carboxymonopeptidase hydrolyzing the cleavage of a single C-terminal residue from Angiotensin-II (Ang-II), the key peptide hormone of RAS, to form Angiotensin-(1-7) (Ang-(1-7)), which binds to the G-protein–coupled Mas receptor and activates signaling pathways that counteract the pathways activated by Ang-II. ACE2 is expressed in a variety of tissues and overwhelming evidence substantiates the beneficial effects of enhancing ACE2/Ang-(1-7)/Mas axis under many pathological conditions in these tissues in experimental models. This review will provide a succinct overview on current strategies to enhance ACE2 as therapeutic agent, and discuss limitations and future challenges. ACE2 also has other functions, such as acting as a co-factor for amino acid transport and being exploited by the severe acute respiratory syndrome coronaviruses (SARS-CoVs) as cellular entry receptor, the implications of these functions in development of ACE2-based therapeutics will also be discussed.

Sign in / Sign up

Export Citation Format

Share Document